The thesis
The premise is simple and intuitive: buy names showing positive recent news sentiment, exit when the tone turns negative. It runs across a 24-name large-cap universe spanning tech, financials, healthcare, staples, and energy — AAPL, MSFT, NVDA, JPM, JNJ, XOM and the like. The logic is defensible: news flow moves prices, and reacting to sentiment shifts is a recognised, if crowded, edge. The strategy is currently live.
Recent activity
Activity is where the character of this strategy shows. In its most active recent session, the 2026-09-23 scheduled run executed two trades — buying 4 shares of NVDA at $225.34 and selling 35 shares of BAC at $55.96 — while rejecting one further candidate. That is the exception, not the rule. The 24th, 22nd, 21st, 18th, and 17th all logged zero executions against one or two rejected candidates each. The portfolio total sits at roughly $10,157 with about $2,037 in cash.
So the engine is running nightly, screening the universe, and mostly deciding to do nothing. That restraint is genuinely a feature — a sentiment strategy that refuses marginal signals avoids churn — but the steady stream of rejections also hints the entry bar may be set too high to compound anything meaningful.
Backtest and validation
Here the numbers demand honesty. Over 451 backtested days the strategy returned just 0.19% (final equity $10,018.55), a 0.1% CAGR, on only 2 trades, with a reported win rate of 0 and total fees of $2. Max drawdown was a trivial 0.05% and turnover 36.5%. The Sharpe of 0.74 and — more encouragingly — an out-of-sample Sharpe of 1.5 with a probabilistic Sharpe (PSR) of 0.923 look respectable in isolation.
But the walk-forward tells the real story. Of four folds, three executed no trades at all, returning flat. Only fold 4 (2025-12-16 to 2026-05-29) actually traded, and every headline metric — the 0.19% return, the 1.5 Sharpe — comes entirely from those two fills. The deflated Sharpe (DSR) of 0.551, adjusted for 6 trials, is far more sober than the raw PSR. Unsurprisingly, formal validation failed: one positive fold out of four is not evidence of a repeatable edge.
Balanced verdict
Strengths: the strategy is disciplined, low-drawdown, cheap to run, and its lone active window produced a clean, positive, high-Sharpe result. It is not overtrading or bleeding on fees.
Risks: the entire track record is two trades. A win rate of zero alongside a positive return is a statistical artefact of that tiny sample, not a signal of skill. Three empty folds mean we simply do not know how this behaves across regimes, and the gap between PSR and DSR warns against reading too much into the raw ratios.
The honest read: a promising idea that has not yet traded enough to be trusted. It has earned a live leash to gather evidence — not capital conviction. The next dozen fills, not the last two, will decide whether news-sentiment is an edge or an accident.